Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Neutrophils in respiratory syncytial virus infection: A target for asthma prevention

Ruben J. Geerdink, MSc,a Janesh Pillay, MD, PhD,b,c Linde Meyaard, PhD,a and Louis Bont, MD, PhDb,d

Utrecht, The Netherlands

Lower respiratory tract infections by respiratory syncytial virus (RSV) are the foremost cause of infant hospitalization and are implicated in lasting pulmonary impairment and the development of asthma. Neutrophils infiltrate the airways of pediatric patients with RSV-induced bronchiolitis in vast numbers: approximately 80% of infiltrated cells are neutrophils. However, why neutrophils are recruited to the site of viral respiratory tract infection is not clear. In this review we discuss the beneficial and pathologic contributions of neutrophils to the immune response against RSV infection. Neutrophils can limit viral replication and spread, as well as stimulate an effective antiviral adaptive immune response. However, low specificity of neutrophil antimicrobial armaments allows for collateral tissue damage. Neutrophil-induced injury to the airways during the delicate period of infant lung development has lasting adverse consequences for pulmonary architecture and might promote the onset of asthma in susceptible subjects. We suggest that pharmacologic modulation of neutrophils should be explored as a viable future therapy for severe RSV-induced bronchiolitis and thereby prevent the inception of subsequent asthma. The antiviral functions of neutrophils suggest that targeting of neutrophils in patients with RSV-induced bronchiolitis is best performed under the umbrella of antiviral treatment. (J Allergy Clin Immunol 2015;136:838-47.)

Key words: Neutrophil, respiratory syncytial virus, asthma, respiratory syncytial virus bronchiolitis, lower respiratory tract infection, neutrophil extracellular traps, immunopathology, asthma prevention, immune regulation, treatment

Neutrophils, the most abundant leukocytes in human circulation, are classically portrayed as unsophisticated, first-line foot soldiers with a role limited to the engulfment and subsequent elimination of invading extracellular bacteria and fungi. In this view lung-infiltrated neutrophils seem out of place during RSV infection. The promiscuous cytotoxicity of neutrophil antimicrobial armaments might even potentiate virus-induced lung injury. Indeed, the degree of neutrophilic inflammation correlates with disease severity in

Respiratory syncytial virus (RSV) is a ubiquitous seasonal human pathogen that, on infection of the upper respiratory tract, causes cold-like symptoms in most healthy adults and children. At 2 years of age, nearly all children will have been infected with RSV at least once. Lower respiratory tract infections (LRTIs) by RSV are a major cause of morbidity and mortality among infants. Annual RSV-associated mortality is estimated at a quarter million deaths per year, of which 99% occur in developing countries, and it accounts for approximately 7% of deaths among infants younger than 1 year of age. In the developed world 1% to 2% of infants are admitted to the hospital with RSV-induced bronchiolitis; therefore it is the foremost cause of infant hospitalization during the winter season. Severe RSV-induced bronchiolitis in infancy is linked to impaired lung function in adulthood and causally implicated in the onset of recurrent wheezing and asthma.

Massive pulmonary neutrophil infiltration is observed in pediatric patients with RSV-induced bronchiolitis. In the lower airways neutrophils account for a median of 76% of infiltrated cells and a median of 93% in the upper airways, as measured in bronchoalveolar lavage fluid and nasopharyngeal aspirates, respectively. Similarly, postmortem histopathologic analyses of fatal RSV-related LRTI cases reveal extensive neutrophil infiltration of the airway wall and lumen, as well as the alveoli. This begs the question of why neutrophils are recruited en masse to the site of viral respiratory tract infection. A wide variety of inflammatory stimuli purposefully attract neutrophils to the lungs, such as to clear invading bacteria, apoptotic debris, or foreign substances. Could neutrophils also function protectively during RSV infection?

NEUTROPHILS AND RSV-INDUCED BRONCHIOLITIS DISEASE SEVERITY

Neutrophils, the most abundant leukocytes in human circulation, are classically portrayed as unsophisticated, first-line foot soldiers with a role limited to the engulfment and subsequent elimination of invading extracellular bacteria and fungi. In this view lung-infiltrated neutrophils seem out of place during RSV infection. The promiscuous cytotoxicity of neutrophil antimicrobial armaments might even potentiate virus-induced lung injury. Indeed, the degree of neutrophilic inflammation correlates with disease severity in
patients with RSV-induced bronchiolitis. Moreover, a common single nucleotide polymorphism just upstream of the IL-8–encoding gene that is tentatively associated with increased production of IL-8, a potent neutrophil chemoattractant, is more frequent among infants with severe RSV-induced bronchiolitis, in particular among infants who lack other known risk factors. Increased IL-8 levels in the airways of patients with bronchiolitis are linked to increased disease severity, as measured based on oxygen saturation, Silverman score, and respiratory rate. Genes related to neutrophil function, such as those encoding α-defensin-1 and elastase, are overexpressed in the blood of patients with RSV-induced bronchiolitis, and expression levels positively correlate with disease severity. Thus neutrophils are thought to contribute to lung injury in patients with severe RSV-induced bronchiolitis, but their exact role in pathogenesis is still unclear.

**CLINICAL LINK BETWEEN RSV-INDUCED BRONCHIOLITIS AND ASTHMA INCEPTION**

A large body of epidemiologic evidence, including prospective case-control and cohort studies, implicates RSV-induced bronchiolitis during infancy in the inception of recurrent wheeze and lasting lung function impairment. However, the association between wheeze and a history of RSV-induced bronchiolitis during infancy partially subsides with age. It is not clear to what extent RSV-induced bronchiolitis is related to increased risk of asthma at school age or beyond. Nonetheless, nearly half of children with severe RSV-induced bronchiolitis present with asthma at 6 years of age. Estimates indicate that early-life RSV-induced bronchiolitis is responsible for up to 13% of childhood asthma cases. Moreover, smoking adults with RSV-induced bronchiolitis during infancy, but not those without LRTIs in early life, have an increased risk of persistent asthma. However, association does not necessarily imply causation. Severe RSV-induced bronchiolitis could occur mainly in infants with pre-existing susceptibility to asthma development. Common genetic and/or environmental factors appear to underlie predisposition to both diseases.

We recently addressed the issue of causality in a randomized, double-blind, placebo-controlled clinical trial with RSV immunoprophylaxis of healthy preterm infants, in which we demonstrated a causal relationship between RSV-induced bronchiolitis and the development of recurrent wheeze. Although wheezing in early life is a strong risk factor for asthma in (early) adulthood, asthma trials are needed to provide conclusive evidence that RSV disease is causally related to persistent asthma.

**NEUTROPHILIC LUNG INFLAMMATION AND ASTHMA INCEPTION**

Neutrophils play an important role in asthma exacerbations by inducing mucus hypersecretion and airway remodeling, which result in acute reversible and progressive irreversible airway obstruction, respectively. Although neutrophils are thought to affect lung function decrease, their role in asthma inception during viral bronchiolitis is understudied. Nonetheless, the severity of infant bronchiolitis shows a dose-response relationship with the risk and morbidity of childhood asthma, and as discussed above, the degree of neutrophilic inflammation correlates with the severity of RSV-induced bronchiolitis. Therefore severe neutrophilic lung inflammation during infancy could tenably predispose children to subsequent wheezing and onset of asthma. Indeed, a functional IL-8 polymorphism more frequent among infants with severe RSV-induced bronchiolitis is also overrepresented in infants who had postbronchiolitis wheezing compared with patients with bronchiolitis who did not have wheezing afterward. Neutrophilic inflammation–induced collateral tissue damage and airway sensitization could mediate the development of asthma susceptibility.

Transient damage to development of infant lungs can have far-reaching and lasting adverse consequences for pulmonary anatomy and function; this is particularly true if the critical process of alveolar multiplication by septation is disrupted. Elastin fibers, which are present in alveolar duct and septal walls, provide elasticity to the lungs and transmit cues of mechanical stress to stimulate alveolarization. Neutrophil elastase, which is released on neutrophil recruitment to the lungs, degrades elastin fibers and thereby demolishes lung tissue structure. Through elastase release and other lung-damaging mechanisms discussed below, the massive pulmonary neutrophil infiltrate of pediatric patients with RSV-induced bronchiolitis might thus cause irreparable disruption of lung development that predisposes these infants to subsequent asthma inception. In addition to inducing airway remodeling through collateral tissue damage, neutrophils might sensitize the airways to asthma through mast cell recruitment. IL-9 is detected in the bronchoalveolar lavage fluid of patients with RSV-induced bronchiolitis, and airway-infiltrated neutrophils are the principal producers. In response to pulmonary expression of IL-9, long-lived mast cells migrate to and accumulate in lung tissue. Lung-resident mast cells, specifically those located in the bronchial smooth muscle bundles, contribute to airway hyperresponsiveness and are considered crucial to the pathogenesis of (allergic) asthma.

Dampening excessive neutrophilic inflammation during RSV-induced bronchiolitis might protect lung function, curtail airway sensitization, and reduce the risk of recurrent wheezing and asthma. A proof-of-concept, randomized, double-blind, placebo-controlled trial of macrolide treatment in patients with RSV-induced bronchiolitis provides tentative clinical support in favor of dampening neutrophilic inflammation. Macrolides have anti-neutrophilic activities in vitro and attenuate neutrophilic airway inflammation in patients with refractory asthma and during RSV infection in mice. In comparison with placebo-treated patients, macrolide-treated patients with RSV-induced bronchiolitis showed reduced nasal lavage IL-8 levels, experienced fewer indications of neutrophilic lung inflammation, and experienced less severe asthma exacerbations.

**Abbreviations used**

- DC: Dendritic cell
- HNP: Human neutrophil peptide
- LRTI: Lower respiratory tract infection
- MMP: Matrix metalloproteinase
- MPO: Myeloperoxidase
- NET: Neutrophil extracellular trap
- NK: Natural killer
- PTX: Pentraxin
- ROS: Reactive oxygen species
- RSV: Respiratory syncytial virus
- TLR: Toll-like receptor
days after bronchiolitis with respiratory symptoms, tended toward fewer subsequent wheezing episodes, and exhibited a delayed third wheezing episode. RSV immunoprophylaxis is costly and available only to high-risk infants, for whom it reduces RSV-related hospitalization by approximately 50%. For patients, supportive care is the sole treatment regimen available. Clearly, new treatment options for severe RSV-induced bronchiolitis are required to ameliorate disease and reduce sequelae, asthma in particular. The prominent neutrophilic inflammation in patients with RSV-induced bronchiolitis represents a promising target.

Below, we examine the role of neutrophils in patients with RSV infection and discuss the relevance thereof for therapy and asthma prevention. Because studies performed with RSV in this regard are scarce, we will also draw information from the literature on other viruses, in particular influenza virus, infections with which also exhibit severe pulmonary neutrophil infiltration.

**NEUTROPHIL-INDUCED LUNG INJURY**

Neutrophils can injure the lungs in multiple ways: (1) release of proteolytic enzymes, including elastase, into the microenvironment through degranulation; (2) production of reactive oxygen species (ROS); (3) formation of neutrophil extracellular traps (NETs) by the cell death program known as NETosis; and (4) stimulation of mucus production (Fig 2).

Neutrophil migration into the airways during influenza infection in mice depends on the neutrophil tertiary granule-expressed matrix metalloproteinase (MMP) 9, which digests extracellular...
matrix. MMP9-mediated neutrophil influx into the airways is required for the control of influenza virus replication in mouse lungs.\textsuperscript{48} However, excessive MMP9 proteolytic activity in response to high viral loads exacerbates pathology.\textsuperscript{48} Pulmonary inflammation caused by noninfectious agents, such as cigarette smoke, implicate other neutrophil proteolytic enzymes, including cathepsin G, neutrophil elastase, and proteinase 3, in lung tissue destruction as well.\textsuperscript{59}

The inflammatory milieu in the lungs during RSV infection induces the neutrophil oxidative burst.\textsuperscript{50} The abundantly produced ROS indiscriminately oxidize biomolecules, which compromises their function. Therefore ROS are potently antimicrobial but also damage host cellular structures. Oxidative stress during RSV infection promotes lung injury.\textsuperscript{1,5} Thus neutrophil-derived ROS are likely to contribute to lung damage in patients with RSV infection.

NETs are DNA-based meshes decorated with histones and granular antimicrobial proteins and peptides, including elastase, myeloperoxidase (MPO), and α-defensins. By trapping microbes in NETs, microbial spread can be minimized and microbe killing optimized by high local concentrations of antimicrobial proteins and peptides.\textsuperscript{53,54} Exposure of neutrophils to RSV particles \textit{in vitro} induces NET formation through specific interaction of RSV fusion (F) protein with neutrophil-expressed Toll-like receptor (TLR) 4.\textsuperscript{55} Data on the \textit{in vivo} antiviral activity of NETs are conflicting.\textsuperscript{56} Genetic ablation of peptidylarginine deiminase 4, which is required for NET formation, did not affect viral replication or mortality in mice infected with influenza virus.\textsuperscript{56} Instead, NETs are located in areas of alveolar damage in the lungs of influenza virus–infected mice.\textsuperscript{57} \textit{In vitro} NETs directly damage alveolar epithelial and endothelial cells. The histone component of NETs is chiefly responsible for this cytotoxic effect.\textsuperscript{58} This suggests that NETs induce lung injury rather than suppressing viral replication. However, the absence of NETs in peptidylarginine deiminase 4–deficient mice does not reduce lung pathology during influenza infection either.\textsuperscript{56} In this mouse model of human influenza virus infection, NETs appear to play neither a beneficial nor a pathologic role. The contribution of NETs during viral infection might be virus specific and depend on the degree of NET induction.

In addition to directly damaging the respiratory tract, neutrophils can contribute to airway obstruction by inducing mucus production. Mucus forms a protective barrier to viral infection by limiting access of viral particles to the pulmonary epithelium. However, excessive mucus production might cause airway obstruction. Mouse neutrophils promote the expression of mucus, the chief component of mucus, during RSV infection.\textsuperscript{59} Thus the extensive neutrophil infiltration in the lungs might contribute to the airway obstruction and resultant wheezing observed in patients with severe RSV-induced bronchiolitis.

Pulmonary IL-17 enhances neutrophil recruitment to the lungs early in RSV infection by inducing IL-8 production in airway epithelial cells.\textsuperscript{60} The amount of IL-17 in the lungs of pediatric patients with RSV-induced bronchiolitis correlates to the degree of subsequent pulmonary neutrophil influx.\textsuperscript{60} Additionally, IL-17 induces the production of obstructive mucus in the airways.\textsuperscript{61} This suggests that IL-17 plays a pathogenic role during LRTIs by RSV. The association of a polymorphism in the gene encoding IL-17 with severe RSV-induced bronchiolitis supports this notion.\textsuperscript{62} Moreover, the response of T<sub>H</sub>17 cells, noted producers of IL-17, is enhanced in infants with RSV-induced bronchiolitis.\textsuperscript{63} An RSV mouse model also links IL-17 and T<sub>H</sub>17 responses to RSV disease severity: pulmonary neutrophil recruitment and lung pathology are exacerbated in RSV-infected mice, which have increased T<sub>H</sub>17 responses caused by genetic ablation of the IL-27 receptor.\textsuperscript{64} Moreover, genetic ablation or antibody-mediated blocking of IL-17 in RSV-infected mice reduces neutrophilic inflammation, mucus production, and viral loads and improves the cytotoxic T-cell response against RSV.\textsuperscript{65} Nonetheless, it is not clear whether local IL-17 levels are protective or harmful. IL-17 reduces airway reactivity of RSV-infected mice presensitized with ovalbumin,\textsuperscript{66} and mice that received a novel attenuated \textit{Bordetella pertussis} vaccine were protected from RSV infection in an IL-17–dependent fashion.\textsuperscript{67} It is possible that a limited IL-17 response is protective, whereas excessive IL-17 production induces immune pathology through unrestrained neutrophil recruitment. However, the early recruitment of neutrophils to the lungs of patients with RSV-induced bronchiolitis is unlikely to be mediated by an adaptive T<sub>H</sub>17 response because RSV antigen–driven clonal expansion and differentiation of T<sub>H</sub>17 cells require several days. Instead, there might be a role for natural T<sub>H</sub>17 cells that acquire effector functions during thymic development and regulate early-phase airway neutrophil responses.\textsuperscript{68,69} Thus (natural) T<sub>H</sub>17 cells and IL-17 might promote a pathogenic neutrophil-dominated response to RSV infection.

**CONTROL OF VIRAL REPLICATION BY NEUTROPHILS**

The neutrophil antimicrobial arsenal, although damaging to the lungs if deployed excessively, has also shown efficacy against viruses in addition to its traditional bacterial and fungal targets. Based on this, a contribution of neutrophils to antiviral defense is suggested.\textsuperscript{55,70,71} Indeed, a beneficial role for neutrophils in patients with viral respiratory tract infections has been reported for influenza virus.\textsuperscript{72,75} Neutrophil depletion in mice by neutrophil-specific anti-Ly6G antibody treatment results in enhanced viral replication and lung damage.\textsuperscript{72} Therefore neutrophil recruitment to the airways during RSV infection could also be a protective response. Neutrophils mediate direct antimicrobial effects through, in essence, 3 known effector mechanisms, namely (1) phagocytosis, (2) degranulation, and (3) NET formation (Fig 2 and Table I).\textsuperscript{76-86} By means of phagocytosis, neutrophils can eliminate RSV-infected cells, thereby preventing further viral replication, and engulf virions to limit infection of new cells. Blocking the recognition and phagocytosis of apoptotic cells by local Annexin V administration 1 day after influenza virus inoculation increases mortality among mice.\textsuperscript{76} Both mouse macrophages and neutrophils phagocytose influenza virus–infected apoptotic cells \textit{in vivo}.\textsuperscript{77} This process is amplified by TLR4,\textsuperscript{87} which recognizes RSV F protein expressed on the surfaces of virions and infected cells.\textsuperscript{77} Moreover, as shown \textit{in vitro} for herpes simplex virus, antibody- and complement-mediated opsonization facilitates the phagocytosis of viral particles and virus-infected cells by neutrophils.\textsuperscript{77}

Neutrophil granules contain antimicrobial proteins and peptides, including α-defensins 1 to 4 (or human neutrophil peptides [HNPs] 1-4), cathelicidins (ie, LL-37), pentraxin (PTX) 3, and MPO, which are released into the microenvironment on degranulation.\textsuperscript{86} Neutrophils degranulate in response to \textit{in vitro} stimulation with RSV particles.\textsuperscript{86} HNPs are small, cationic amphipathic
peptides that demonstrate antiviral activity. For instance, multiple steps of cellular entry by HIV-1 are inhibited by HNP-1,78 and HNPs promote influenza virus infection and uptake by neutrophils.79 Whether the antiviral activity of HNPs extends to RSV is not currently known, but the broad antiviral activities of HNPs against multiple enveloped and nonenveloped viruses hints at the possibility.80

Recent in vitro work demonstrates that the cationic antimicrobial peptide LL-37 possesses direct antiviral activity against RSV, protects infected epithelial cells against RSV-induced cell death, inhibits production of new viral particles, and reduces the susceptibility of epithelial cells to RSV infection.80 Low serum levels of LL-37 precursor (ie, hCAP-18) are associated with severe infantile RSV-induced bronchiolitis.81

PTXs are soluble pattern recognition molecules that recognize pathogen-associated molecular patterns and mediate innate humoral immunity, functionally resembling antibodies of the adaptive immune system. PTX3 can activate complement through recruitment of C1q (ie, the classical pathway) and act as opsonins by interacting with the FcγRIII (CD16) and FcγRII (CD32) receptors, which are expressed by phagocytes, including neutrophils.92 Mature neutrophils represent a major reservoir of preformed ready-to-use PTX3, as well as other pattern recognition molecules.93 Direct evidence of PTX3-mediated antiviral activity against RSV is lacking but has been demonstrated for influenza virus and mouse coronavirus. PTX3 reduces the infectivity of both viruses. Moreover, PTX3-deficient mice inoculated with either virus fare worse than their wild-type counterparts but can be rescued by administration of exogenous PTX3.92,93

MPO catalyzes the production of hypochlorous acid, which is a potent antimicrobial ROS, because of its ability to chlorinate and oxidize a great variety of biomolecules. Secreted and NET-bound MPO deactivates HIV-1 particles in vitro.84,85 The RSV F protein induces formation of MPO-coated NETs through TLR4,84 and HIV-1 triggers NETosis through a TLR7/TLR8- and ROS-dependent pathway. NET-bound MPO and HNPs abolish the infectivity of HIV-1 particles. In coculture neutrophils reduce the infection of CD4+ T cells by HIV-1 in a NET-dependent manner.85 Thus NETs are elicited by stimulation with virus and possess direct antiviral activity in vivo.

Furthermore, the release of NETs by neutrophils during intravenous myxoma poxvirus challenge in mice protects against viral infection of liver cells.86 Therefore NETs can benefit antiviral defense in vivo. As discussed above, NETosis deficiency does not affect the course of disease in human influenza virus-infected mice.87 A contribution, protective or damaging, of NETs to antiviral defense might be virus and organ (eg, liver vs lung) specific.

### TABLE I. Neutrophils possess direct antiviral activity

| Mechanism or molecular mediator | Effect and function | Virus/model | References |
|---------------------------------|--------------------|-------------|------------|
| Phagocytosis                     | Eliminates virus-infected cells and virions | Influenza virus/in vivo | 76, 77    |
| HNP-1                           | Inhibits viral entry into cell | HIV/in vitro | 78        |
| HNP-1 and HNP-2                 | Promotes virion aggregation and phagocytosis | Influenza/in vitro | 79        |
| LL-37                           | Inactivates virions, protects epithelial cells from infection and cell death, inhibits virion production | RSV/in vitro and clinical association | 80, 81    |
| PTX3                            | Reduces virion infectivity | Influenza virus and MHV-1/ in vivo and in vivo | 82, 83    |
| MPO                             | Inactivates virions through HClO production | HIV-1/in vitro | 84        |
| NETosis                         | Reduces viral infectivity and spread, inactivates virions | Influenza virus and myxoma poxvirus/in vitro and in vivo | 85, 86    |

Neutrophil effector mechanisms, neutrophil-derived molecules, and their respective antiviral activities are listed. The supporting lines of evidence and related references are included.

### NEOUROPHIL-MEDIATED IMMUNE MODULATION

Recent studies demonstrate multiple immune regulatory functions for neutrophils. In addition to their role as effector cells in patients with RSV infection described above, neutrophils can also act as immune regulatory cells (Fig 3). Although neutrophil-mediated immune regulation in the context of RSV infection has yet to be examined directly, general concepts can be derived from studies with other viruses and guide further research into the severely understudied role of neutrophils in patients with RSV infection. Here we focus on regulatory roles potentially involved in RSV infection. For a more complete overview, the reader is referred to a number of recent reviews.89,93-95

Neutrophils can promote antiviral CD8+ T-cell responses. Influenza virus antigen–displaying neutrophils stimulate lung-infiltrated CD8+ T cells to produce IFN-γ, whereas infected epithelial cells only elicit their own cytolyis.96,97 Stimulation of IFN-γ production by neutrophils can enhance antiviral defense against RSV infection.98 The CD8+ T-cell response to influenza in the Airways of mice is maintained by infiltrated neutrophils.75 Neutrophils thus regulate CD8+ T-cell effector function at the site of viral infection. Neutrophils efficiently cross-present phagocytosed antigen to naive CD8+ T cells in vivo to stimulate proliferation, IFN-γ production, and cytolytic activity.99 By acting as viral antigen shuttles, neutrophils can indirectly induce an antiviral CD8+ T-cell response. Mouse neutrophils take up modified vaccinia Ankara virus in skin, transport viral antigen to the bone marrow, and there, through local phagocytic antigen-presenting cells, trigger virus-specific CD8+ T-cell proliferation and establishment of memory.100 Moreover, neutrophils can indirectly stimulate T-cell responses by recruiting immature dendritic cells (DCs) to a site of infection through CCL3 secretion101 and by inducing DC maturation through direct cell-cell contact, which depends on altered glycosylation patterns of Mac-1 (CD11b/CD18) and carcinoembryonic antigen-related cell adhesion molecule 1 (CAECAM1) that are specific to activated neutrophils.102,103

The homeostasis of innate cytotoxic lymphocytes (ie, natural killer [NK] cells) is neutrophil dependent.104-106 Neutropenic patients and neutrophil-depleted mice present with immature hyporesponsive NK cells.104 Neutrophils stimulate NK cells through IL-18 production and the interaction of...
CD18 with NK cell–expressed intercellular adhesion molecule 3. Moreover, neutrophils stimulate DCs to produce NK cell–stimulatory IL-12 through CD18/intercellular adhesion molecule (ICAM) 1 interaction. IFN-γ produced by activated NK cells potentiates the interaction between neutrophils and DCs, thus creating a neutrophil-dependent positive feedback loop that supports NK cell maturation, survival, and IFN-γ production.
The adaptive humoral response is stimulated by neutrophils as well. Through cytokine secretion (ie, B cell–activating factor of the TNF family [BAFF], a proliferation inducing ligand [APRIL], and IL-21), splenic neutrophils induce immunoglobulin class-switch recombination, somatic hypermutation, and antibody production by marginal zone B cells.107 Neutrophils can also suppress adaptive immune responses. Systemic inflammation in human subjects induces a neutrophil subset with T cell–suppressive capabilities. These suppressive neutrophils form Mac-1–dependent immunologic synapses with T cells and locally produce bursts of membrane-associated hydrogen peroxide (H2O2) that suppress T-cell proliferation.108 Furthermore, neutrophil-derived thromboxane limits T-cell cytokine production in response to protein-in-adjuvant vaccination of mice and suppresses the spread of the T-cell response from the draining lymph nodes of the injection site to distal lymph nodes.109 Neutrophils can indirectly suppress T-cell responses through deposition of MPO in lymph nodes, which impairs DC function.10

In a more passive manner neutrophils might contribute to the resolution of inflammation. Depending on environmental stimuli, macrophages can acquire a proinflammatory or proresolution phenotype. The phagocytosis of apoptotic neutrophils by macrophages induces a regulatory phenotype in macrophages, which might contribute to the resolution of inflammation.11 In RSV-infected cotton rats, proresolution macrophages limit lung pathology.112

NEUTROPHILS, RSV-INDUCED BRONCHIOLITIS, AND ASTHMA: REMAINING CAVEATS

Is it conceivable that neutrophils are abundantly present in the airways during severe RSV infection without playing a major role in either the pathogenesis of bronchiolitis or the subsequent inception of asthma? Although indicators of neutrophilic inflammation, including airway IL-8 levels and neutrophil elastase activity, correlate with the severity of bronchiolitis, cell counts of airway-infiltrated neutrophils, which are invariably high, are not associated with RSV disease severity.10,13,15,16,113 Similar to RSV-induced bronchiolitis, extensive neutrophil infiltration of the airways and alveoli is observed during bacterial pneumonia, usually in the absence of wheezing. If neutrophils contribute to the inception of asthma after bronchiolitis, an increased risk of asthma should also be observed after bacterial respiratory tract infections in early childhood. Evidence in support of this is limited to observations in a high-risk birth cohort.11 Limited evidence also hints at a causal association between bacterial invasion of the respiratory tract and subsequent asthma development.112 Colization of neonatal airways by pathogenic bacteria induces neutrophil responses—associated cytokines and is associated with development of persistent wheezing and childhood asthma in a prospective birth cohort.124,125 Moreover, among prospectively followed high-risk children, respiratory tract infections by pathogenic bacteria in early life were associated with an increased risk of school-age asthma.31 In fact, rather than a specific viral or bacterial pathogen, the total number of early respiratory tract infections correlated with the risk of childhood asthma in this study.11

Although injurious when present in excess, neutrophils are essential to antimicrobial defense. The safety of treating RSV-induced bronchiolitis with neutrophil suppression could improve with the administration of RSV antivirals and prophylactic antibiotics. Recently, a newly developed RSV antiviral was successfully tested in a clinical trial wherein healthy adult subjects were challenged with RSV.126 By itself, however, an RSV antiviral might confer limited benefit when administered several days after onset of symptoms. For influenza, oseltamivir is only effective when administered within 36 to 48 hours after symptom onset.121 Similarly, antiviral treatments against RSV should ideally be administered as close to initial infection as possible to be at their most effective, yet RSV loads are already on the decrease when patients are admitted to the intensive care unit.128 Nonetheless, neutrophils are still abundantly present in the lungs,11 and thus neutrophil–mediated damage to the airways persists (Fig 2). Therefore we propose that suppressing neutrophil activity under the umbrella of RSV antivirals and prophylactic antibiotics offers a promising treatment strategy to improve the outcomes of infants with RSV-induced bronchiolitis and reduce the risk of subsequent asthma.

CONCLUDING REMARKS AND IMPLICATIONS FOR THERAPY

The vast number of lung-infiltrating neutrophils in patients with RSV-induced bronchiolitis appears to be the principal instigator of pulmonary immunopathology. The secretion of proteolytic enzymes, such as elastase, the production of ROS, and NET release can clearly injure the lungs. This might disrupt the delicate process of lung development in infancy and have lasting adverse consequences for lung anatomy, function, and susceptibility to chronic disease, including asthma. However, through direct antiviral activity of these and other neutrophil mechanisms, as well as through regulation of adaptive immune responses, neutrophils can also contribute to a protective antiviral response. In patients with severe RSV-induced bronchiolitis, the balance between neutrophil antimicrobial activity and collateral tissue damage appears to have shifted toward a pathologic response. Hence pharmacologic suppression of neutrophil activity could curtail lung injury. Possible approaches include (1) neutrophil-inhibitory macrolides43,46, (2) inhibiting damaging neutrophil-derived products, such as elastase114, (3) antagonizing neutrophil-modulatory adenosine115, (4) neutrophil chemokine receptor blockade16,117, (5) and targeting neutrophil-expressed inhibitory receptors.118,119 We eagerly await the results of future clinical trials for the treatment of RSV infection with pharmacologic agents that can effectively dampen neutrophil inflammation, such as the selective small-molecule CXCR2 (IL-8 receptor) antagonist danrixin (ClinicalTrials.gov identifier: NCT02201303).117

The relationship between extensive neutrophil infiltration of the airways in early life and later asthma development might not be limited to RSV infection. Lower respiratory tract illnesses in infants induced by other viruses are also associated with subsequent wheeze and asthma.31,120 Limited evidence also hints at a causal association between bacterial invasion of the respiratory tract and subsequent asthma development.121,125 Colonization of neonatal airways by pathogenic bacteria increases neutrophil response–associated cytokines and is associated with development of persistent wheezing and childhood asthma in a prospective birth cohort.124,125 Moreover, among prospectively followed high-risk children, respiratory tract infections by pathogenic bacteria in early life were associated with an increased risk of school-age asthma.31 In fact, rather than a specific viral or bacterial pathogen, the total number of early respiratory tract infections correlated with the risk of childhood asthma in this study.11

Although injurious when present in excess, neutrophils are essential to antimicrobial defense. The safety of treating RSV-induced bronchiolitis with neutrophil suppression could improve with the administration of RSV antivirals and prophylactic antibiotics. Recently, a newly developed RSV antiviral was successfully tested in a clinical trial wherein healthy adult subjects were challenged with RSV.126 By itself, however, an RSV antiviral might confer limited benefit when administered several days after onset of symptoms. For influenza, oseltamivir is only effective when administered within 36 to 48 hours after symptom onset.121 Similarly, antiviral treatments against RSV should ideally be administered as close to initial infection as possible to be at their most effective, yet RSV loads are already on the decrease when patients are admitted to the intensive care unit.128 Nonetheless, neutrophils are still abundantly present in the lungs,11 and thus neutrophil–mediated damage to the airways persists (Fig 2). Therefore we propose that suppressing neutrophil activity under the umbrella of RSV antivirals and prophylactic antibiotics offers a promising treatment strategy to improve the outcomes of infants with RSV-induced bronchiolitis and reduce the risk of subsequent asthma.

REFERENCES

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
2. Smyth RL, Openshaw PJ. Bronchiolitis. Lancet 2006;368:312-22.
3. Hervás D, Reina J, Yániz A, del Valle JM, Figuerola J, Hervás JA. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis 2012;31:1975-81.

4. Blanken MO, Rovers MM, Bont L. Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze. N Engl J Med 2013;369:782-3.

5. Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 2012;130:913-3.

6. Backman K, Fippo-Savalainen E, Olikainen H, Koskela H, Korppi M. Adults face increased asthma risk after infant RSV bronchiolitis and reduced respiratory health-related quality of life after RSV pneumonia. Acta Paediatr 2014;103:850-5.

7. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354:541-5.

8. Everard ML, Milner AD. The respiratory syncytial virus and its role in acute bronchiolitis. Eur J Pediatr 1992;151:638-61.

9. Everard ML, Swarbrick A, Wrightham M, McIntyre J, Dunkley C, James PD, et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child 1994;71:428-32.

10. McNamara PS, Ritson P, Selby A, Hart CA, Smyth RL. Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis. Arch Dis Child 2003;88:922-6.

11. Welliver TR, Garofalo RP, Hosakote Y, Hintz KH, Avendano L, Sanchez K, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007;195:1126-36.

12. Baroel BW, Kenny EF, Sollberger G, Zychlinsky A. The balancing act of neutrophil and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007;195:1126-36.

13. Yacoub K, Baba A, Iwasaki Y, Kubo T, Aoyama K, Mori T, et al. Neutrophil-mediated inflammation in respiratory syncytial viral bronchiolitis. Pediatr Int 2005;47:190-5.

14. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000;55:1023-7.

15. Marguet C, Bocquel N, Benichou J, Basuyau JP, Hellot MF, Couderc L, et al. Interleukin-9 production in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 2011;127:AB136.

16. Smyth RL, Mobbs KJ, O’Hea U, Ashby D, Hart CA. Respiratory syncytial virus infection. Arch Dis Child 1994;71:428-32.

17. Mejias A, Dimo B, Suarez NM, Garcia C, Suarez-Arrabal MC, Jartti T, et al. Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus bronchiolitis. Arch Dis Child 2003;88:922-6.

18. Nicholas C, Wegienka G, Havstad S, Zoratti E, Ownby D, Johnson CC. Are severe pulmonary infections in the first year of life. Thorax 2010;65:1045-52.

19. Segura S, Yao W, Nguyen ET, Glosson-Byers NL, Ahtuar N, Zhou B, et al. TH9 cells are required for tissue cell mass accumulation during allergic inflammation. J Allergy Clin Immunol 2011;135:1711-8.e1.

20. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010;138:1202-12.

21. Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2009;123:131-7.

22. Carroll KN, Wu P, Gebretsadik T, Griffin MR, Dupont WD, Mitchel EF, et al. The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. J Allergy Clin Immunol 2009;123:1055-61.e1.

23. Nicholas C, Wiegenk A, Hovsdotd S, Zoratti E, O’Hara D, Johnson CC. Are severe lung infections in the first 2 years of life related to lung function at 18 years. J Allergy Clin Immunol 2011;127:AB136.

24. James KM, Gebretsadik T, Escobar GI, Wu P, Carroll KN, Li SX, et al. Risk of childhood asthma following bronchiolitis during the respiratory syncytial virus season. J Allergy Clin Immunol 2013;132:227-9.

25. Zomer-Kooijker J, van der Ent CK, Ermers M. Increased risk of wheeze and decreased lung function after respiratory syncytial virus infection. PLoS One 2014;9:e87162.

26. Voraphani N, Stern DA, Wright AL, Guerra S, Morgan WJ, Martinez FD. Risk of current asthma among adult smokers with respiratory syncytial virus illnesses in early life. Am J Respir Crit Care Med 2014;190:392-8.

27. Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV. Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Am J Respir Crit Care Med 2015;191;845.

28. Wu P, Hartert TV. Evidence for a causal relationship between respiratory syncytial virus infection and asthma. Expert Rev Anti Infect Ther 2011;9:731-45.

29. Sigurs N, Bjarnason R, Sigurbergsson F; Kjellman B, Bjorkstén B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995;95:500-5.

30. Henderson J, Hilliard TN, Sherriff A, Stalker D, Shammar Al N, Thomas HM. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol 2005;16:386-92.

31. Brennecke K, Vissing NH, Sevelsted A, Johnsten SL, Bisgaard H. Association between respiratory infections in early life and later asthma is independent of virus type. J Allergy Clin Immunol 2015;136:81-6.e4.

32. Régner SA, Huel J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J 2013;32:820-6.

33. Stern DA, Morgan WJ, Halonen M, Wright AL, Martinez FD. Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in early adulthood: a longitudinal birth-cohort study. Lancet 2008;372:1058-64.

34. Louis R, Djukanovic R. Is the neutrophil a worthy target in severe asthma and chronic obstructive pulmonary disease? Clin Exp Allergy 2006;36:563-7.

35. Beek KM, Beier J. Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma. Clin Exp Allergy 2006;36:142-57.

36. Goetgebuer T, Iles K, Moore C, Thomson A, Kwiatkowski D, Hull J. Genetic predisposition to wheeze following respiratory syncytial viral bronchiolitis. Clin Exp Allergy 2004;34:301-3.

37. Le Cais TD, Hardie WD, Deutsch GH, Albertine KH, Begami M, Whitsett JA, et al. Transient induction of TGF-alpha disrupts lung morphogenesis, causing pulmonary disease in adulthood. Am J Physiol Lung Cell Mol Physiol 2004;287:L718-29.

38. Cavara E, Martorana PA, Gambelli F, de Santi M, Van Even P, Lunegarella G. Neutrophil recruitment into the lungs is associated with increased lung elastase burden, decreased lung elastin, and emphysema in alpha 1 proteinase inhibitor-deficient mice. Lab Invest 1996;75:273-80.

39. McNamara PS, Flanagan BF, Baldwin LM, Newland P, Hart CA, Smyth RL. Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus bronchiolitis. Lancet 2004;363:1031-7.

40. Kearley J, Erjefalt JS, Anderson C, Benjamin E, Jones CP, Robichaud A, et al. IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med 2011;183:865-75.

41. Segura S, Yao W, Nguyen ET, Glosson-Byers NL, Ahtuar N, Zhou B, et al. TH9 cells are required for tissue cell mass accumulation during allergic inflammation. J Allergy Clin Immunol 2015;136:433-40.

42. Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006;117:1277-84.

43. Flegel MA, Isacsson G, Christi M, Sajid M, Bady J, Rodriguez OM, Leege E, et al. Randomized trial to evaluate azithromycin’s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 2015;135:1711-8.e1.

44. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010;138:1202-12.

45. Beigelman A, Mikols CL, Gunsten SP, Cannon CL, Brody SL, Walter MJ. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. Respir Res 2010;11:90.
52. Hosakote YM, Jantzi PD, Edshum DL, Spratt H, Kurosky A, Casola A, et al. Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2011;183:1550-60.

53. Brinkmann V, Reichard U, Goosmann C, Fauvert B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1352-5.

54. Fuchal AJ, Gafer N, Czepielewski RS, Machado MS, Muraro SP, Stein RT, et al. Respiratory syncytial virus fusion protein promotes TLR4-dependent neutrophil extracellular trap formation by human neutrophils. PLoS One 2015;10:e24082.

55. Jenne CN, Kubes P. Virus-induced NETs—critical component of host defense or pathogenic mediator? PLoS Pathog 2015;11:e1004546.

56. Hemmers S, Teijaro JR, Arandjelovic S, Mowen KA. PAD4-mediated neutrophil extracellular trap formation is not required for immunity against influenza infection. PLoS One 2011;6:e22043.

57. Narasaraju M, Juennemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One 2012;7:e32366.

58. Stokes KL, Currie MG, Sakamoto K, Lee S, Collins PL, Peusper RK, et al. The respiratory syncytial virus fusion protein and neutrophils mediate the airway muco-glandular response to pathogenic respiratory syncytial virus infection. J Virol 2013;87:10070-82.

59. Stoppelenburg AJ, Salimi V, Hennus M, Plantinga M, Huis In’t Veld R, Walk J, et al. Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus type-1. PLoS Pathog 2015;11:e1004546.

60. Saffarzadeh M, Juenemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One 2011;6:e22043.

61. Saffarzadeh M, Juenemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One 2011;6:e22043.

62. Stoppelenburg AJ, de Roock S, Hennus MP, Bont L, Boes M. Elevated Th17 cells to the site of inflammation in the lung. Mucosal Immunol 2012;5:258-66.

63. Stoppelenburg AJ, de Roock S, Hennus MP, Bont L, Boes M. Elevated Th17 cells to the site of inflammation in the lung. Mucosal Immunol 2012;5:258-66.

64. De Almeida Nagata DE, Demoor T, Ptaschinski C, Ting HA, Jang S, Reed M, et al. Neutrophil-derived CCL3 is essential for the rapid recruitment of dendritic cells to the site of Leishmania major inoculation in resistant mice. PLoS Pathog 2010;6:e1000755.

52. Hosakote YM, Jantzi PD, Edshum DL, Spratt H, Kurosky A, Casola A, et al. Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2011;183:1550-60.

53. Brinkmann V, Reichard U, Goosmann C, Fauvert B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1352-5.

54. Fuchal AJ, Gafer N, Czepielewski RS, Machado MS, Muraro SP, Stein RT, et al. Respiratory syncytial virus fusion protein promotes TLR4-dependent neutrophil extracellular trap formation by human neutrophils. PLoS One 2015;10:e24082.

55. Jenne CN, Kubes P. Virus-induced NETs—critical component of host defense or pathogenic mediator? PLoS Pathog 2015;11:e1004546.

56. Hemmers S, Teijaro JR, Arandjelovic S, Mowen KA. PAD4-mediated neutrophil extracellular trap formation is not required for immunity against influenza infection. PLoS One 2011;6:e22043.

57. Narasaraju M, Juennemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One 2012;7:e32366.

58. Stokes KL, Currie MG, Sakamoto K, Lee S, Collins PL, Peusper RK, et al. The respiratory syncytial virus fusion protein and neutrophils mediate the airway muco-glandular response to pathogenic respiratory syncytial virus infection. J Virol 2013;87:10070-82.

59. Stoppelenburg AJ, Salimi V, Hennus M, Plantinga M, Huis In’t Veld R, Walk J, et al. Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus type-1. PLoS Pathog 2015;11:e1004546.

60. Saffarzadeh M, Juenemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One 2011;6:e22043.
